Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

RSS icon
physician tracking patient data and reporting on outcomes

Q&A: Cardiologist Karen Joynt Maddox on why new healthcare policies are not improving outcomes

Healthcare's ongoing shift toward value-based care is a good thing, Joynt Maddox explained, but its implementation has been far from ideal. She also discussed population health, the pandemic, health disparities and the rising influence of private equity investments.

covid cancer connection

Does Covid-19 raise risk for cancers—including rare ones?

A growing set of anecdotes has some physicians suspecting a link.

FDA panel recommends new COVID-19 booster

Booster uptake rates remain low. To date, only 22.5% of Americans received an annual COVID-19 shot from 2023.

Heart Rhythm Society (HRS) President Kenneth Ellenbogen, MD, FHRS, director of clinical cardiac electrophysiology and pacing, Virginia Commonwealth University, discussed two key initiatives for 2024-25 with Cardiovascular Business. These include helping create a new, independent cardiovascular medicine board, and supporting the movement toward more outpatient procedures being performed in office-based labs (OBL) and ambulatory surgical centers (ASC). #EPeeps #HRS #HRS24 #HRS2024

Heart Rhythm Society shows support for new cardiovascular board, outpatient EP centers

Cardiovascular Business spoke with HRS President Kenneth Ellenbogen, MD, about two key initiatives the group is focused on this year.

M&A mergers and acquisitions business deal

Edwards Lifesciences sells critical care business to BD for $4.2B—remains ‘laser focused’ on structural heart disease

This move represents a pivot of sorts for Edwards; instead of pursuing a spin-off of its critical care business, the company is now doubling down on its commitment to develop new structural heart technologies. BD, meanwhile, says the transaction will deliver significant value. 

Thumbnail

Cardiology salaries keep rising, outpacing consumer prices—interventional cardiologists see biggest jump

Cardiology's gains are far less than some specialties—pay for dermatologists went up more than 10%, for instance—but still ahead of the consumer price index.

Richard Heuser, MD, an interventional cardiologist known for his groundbreaking work in the field, leadership and strong business acumen, died on May 23. He was 73 years old.

Cardiologist Richard Heuser, interventional specialist and medical device pioneer, dies at 73

Heuser had a long, impactful career in cardiology. One former colleague said he was “an amazing interventional cardiologist and an even better human being.”

cleveland clinic settles for failing to disclose research funding

Cleveland Clinic paying $7M+ to settle deceptive funding case

A Cleveland Clinic researcher accepted NIH funding without telling the agency about money coming in for the same project from one or more foreign backers. For this the nonprofit Cleveland Clinic Foundation will pay $7.6 million.

Displaying 81 - 88 of 683

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup